



**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91-22) 2826 6000  
Fax: (91-22) 2826 7337  
Website: in.pg.com

**April 28, 2022**

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001  
**Ref:- Scrip Code:- 500459**

The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400051  
**Ref:- Scrip Code:- PGHH**

Dear Sir / Madam,

**Sub:- Unaudited Financial Results for the quarter ended March 31, 2022**

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 12.30 pm and ended at 1.30 pm), the Unaudited Financial Results for the quarter ended March 31, 2022 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended March 31, 2022;
- b. Press Release;
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2022 furnished by Statutory Auditors of the Company; and

Kindly take the same on record and oblige.

Thanking you.

Yours faithfully,  
***For Procter & Gamble Hygiene and Health Care Limited***

***Ghanashyam Hegde***  
***Director and Company Secretary***



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st MARCH 2022

(₹ In Lakhs)

| Particulars   | (1)  | (2)  | (3)  | (4)   | (5)   | (6)  |
|---|--|--|--|---|---|--|
|   | Three Months Ended 31st Mar 2022 (Unaudited) | Preceding Three Months Ended 31st Dec 2021 (Unaudited) | Corresponding Three Months Ended 31st Mar 2021 (Unaudited) | Nine Months Ended 31st Mar 2022 (Unaudited) | Corresponding Nine Months Ended 31st Mar 2021 (Unaudited) | Previous Year Ended 30th June 2021 (Audited) |
| <b>1 Income</b>   |  |  |  |   |   |  |
| Sale of products  | 88 949                                       | 1 09 125   | 75 888   | 3 03 680                                    | 2 78 486  | 3 57 024                                     |
| Other operating revenues (Refer Note 2)   | 8 377  | 172  | 78   | 8 774                                       | 289   | 390  |
| <b>2 Revenue from operations</b>  | <b>97 326</b>                                | <b>1 09 298</b>  | <b>75 966</b>  | <b>3 12 454</b>                             | <b>2 78 755</b>   | <b>3 57 414</b>                              |
| <b>3 Other income</b>   | <b>603</b>                                   | <b>686</b>   | <b>1 475</b>   | <b>1 869</b>                                | <b>3 366</b>  | <b>3 938</b>                                 |
| <b>Total Income (2+3)</b>   | <b>97 929</b>                                | <b>1 09 984</b>  | <b>77 441</b>  | <b>3 14 323</b>                             | <b>2 82 121</b>   | <b>3 61 352</b>                              |
| <b>4 Expenses</b>   |  |  |  |   |   |  |
| a) Cost of raw and packing materials consumed   | 34 715                                       | 35 944   | 24 845   | 1 04 963                                    | 87 546  | 1 12 839                                     |
| b) Purchases of stock-in-trade (Traded goods)   | 10 625                                       | 1 167  | 1 167  | 13 177                                      | 2 771   | 4 113  |
| c) Changes in inventories of finished goods, work-in-progress and stock-in-trade      | ( 766)                                       | 922  | ( 929)   | ( 112)                                      | 470   | ( 1 022)                                     |
| d) Employee benefits expense  | 5 598  | 5 991  | 5 696  | 17 205                                      | 15 980  | 20 168                                       |
| e) Finance costs  | 682  | 294  | 295  | 1 035                                       | 538   | 611  |
| f) Depreciation and amortization expense  | 1 312  | 1 289  | 1 126  | 3 870                                       | 3 504   | 4 766  |
| g) Impairment losses (Refer Note 3)   | —  | —  | 764  | —   | 764   | 764  |
| h) Advertising & sales promotion expenses   | 11 234                                       | 13 862   | 12 958   | 37 432                                      | 32 835  | 52 248                                       |
| i) Other expenses   | 19 419                                       | 21 765   | 18 496   | 63 509                                      | 57 449  | 79 876                                       |
| <b>Total expenses</b>   | <b>82 819</b>                                | <b>81 234</b>  | <b>64 518</b>  | <b>2 41 079</b>                             | <b>2 01 857</b>   | <b>2 74 363</b>                              |
| <b>5 Profit before tax (1-4)</b>  | <b>15 110</b>                                | <b>28 750</b>  | <b>12 923</b>  | <b>73 244</b>                               | <b>80 264</b>   | <b>86 989</b>                                |
| <b>6 Tax expense</b>  |  |  |  |   |   |  |
| a) Current tax  | 4 613  | 7 957  | 3 384  | 20 434                                      | 21 087  | 22 873                                       |
| b) Deferred tax   | ( 499)                                       | ( 413)   | ( 132)   | ( 1 221)                                    | ( 799)  | ( 889)                                       |
| c) Prior year tax adjustments   | 711  | —  | ( 162)   | 711   | ( 305)  | ( 174)                                       |
|   | <b>4 825</b>                                 | <b>7 544</b>   | <b>3 090</b>   | <b>19 924</b>                               | <b>19 983</b>   | <b>21 810</b>                                |
| <b>7 Profit for the period (5-6)</b>  | <b>10 285</b>                                | <b>21 206</b>  | <b>9 833</b>   | <b>53 320</b>                               | <b>60 281</b>   | <b>65 179</b>                                |
| <b>8 Other comprehensive income</b>   |  |  |  |   |   |  |
| Items that will not be reclassified to profit or loss:                                |  |  |  |   |   |  |
| Re-measurement of the defined benefit plans   | 804  | ( 202)   | 861  | 647   | 561   | 179  |
| Income tax effect on above  | ( 202)                                       | 50   | ( 217)   | ( 163)                                      | ( 141)  | ( 45)  |
| <b>Total other comprehensive income for the period</b>                                | <b>602</b>                                   | <b>( 152)</b>  | <b>644</b>   | <b>484</b>                                  | <b>420</b>  | <b>134</b>                                   |
| <b>9 Total comprehensive income for the period (7+8)</b>                              | <b>10 887</b>                                | <b>21 054</b>  | <b>10 477</b>  | <b>53 804</b>                               | <b>60 701</b>   | <b>65 313</b>                                |
| <b>10 Paid-up equity share capital (Face Value ₹ 10 per equity share)</b>             | <b>3 246</b>                                 | <b>3 246</b>   | <b>3 246</b>   | <b>3 246</b>                                | <b>3 246</b>  | <b>3 246</b>                                 |
| <b>11 Other Equity</b>  |  |  |  |   |   |  |
| <b>12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :</b> |  |  |  |   |   |  |
| a) Basic  | 31.68  | 65.33  | 30.29  | 164.26                                      | 185.71  | 200.79                                       |
| b) Diluted  | 31.68  | 65.33  | 30.29  | 164.26                                      | 185.71  | 200.79                                       |

See accompanying notes to the financial results

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on April 28, 2022 and have been subjected to a limited review by the Statutory Auditors of the Company.
- Other operating revenues for the current quarter and the nine months ended March 31, 2022 includes an amount of ₹ 8 199 lakhs on account of sale of materials consequent to the change in the business model from toiler to contract manufacturing.
- During the previous year ended June 30, 2021, Non-Current Assets Held for Sale were fully impaired on a conservative basis since the Company was unable to dispose off the said assets. Consequently, an impairment loss amounting to ₹ 764 lakhs was recognized in the Statement of Profit and Loss for the previous year. These assets continue to be classified as held for sale as at March 31, 2022, since the management intends to dispose off these assets and is actively pursuing the said matter.
- The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.
- Previous period figures have been regrouped / reclassified wherever necessary.

For and on behalf of the Board of Directors of  
Procter & Gamble Hygiene and Health Care Limited

Madhusudan Gopalan  
Managing Director

Place: Mumbai  
Date: April 28, 2022





**Procter & Gamble Hygiene and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai - 400099  
Tel: (91-22) 2826 6000  
Fax: (91-22) 2826 7337  
Website: [in.pg.com](http://in.pg.com)

***Procter & Gamble Hygiene and Health Care Ltd. announces third quarter results***

**Mumbai, April 28, 2022:** Procter & Gamble Hygiene and Health Care Ltd. announced today its financial results for the quarter ended March 31, 2022. The company delivered sales of ₹973 crores, up 28% vs year ago driven by strong brand fundamentals, strength of its trusted product portfolio, strong retail execution and a one-time other income during the quarter from intercompany sale of inventory. Excluding the one-time income, comparable sales are up 17% vs year ago. Profit After Tax (PAT) was ₹103 crores, up 5% driven by continued focus on productivity and a one-time hurt due to retrospective tax law change. Excluding this one-time impact, PAT was up 20% vs year ago, despite commodity inflation.

**Madhusudan Gopalan, Managing Director, Procter & Gamble Hygiene and Health Care Ltd.** said, *“In a challenging market environment, we recorded strong double-digit sales growth driven by strong brand fundamentals and improved market execution. Excluding the one-time impact, our productivity efforts led to a strong double digit profit growth. As we navigate the challenging cost environment, we will continue to focus on improving productivity by leveraging advertising and promotion analytics, strengthening our product mix and driving supply chain efficiencies. In the long-term, we will continue to focus on driving balanced top and bottom-line growth enabled by our superiority strategy, improving productivity, leading constructive disruption, and strengthening our organization and culture.”*

During the quarter, the company’s feminine care brand Whisper launched its new film ‘The Missing Chapter’ as part of its #KeepGirlsInSchool movement. The movement was launched two years ago, highlights how lack of period education forces girls to drop out of school. Continuing this effort, Whisper’s latest campaign ‘The Missing Chapter’ raises awareness about the need for menstrual hygiene education in schools and advocates for mandatory inclusion of period education in school curriculum. For over 3 decades, since its launch in India, Whisper has educated over 5.5 crore girls on the importance of menstrual hygiene.

**About Procter & Gamble Hygiene and Health Care Ltd.**

Procter & Gamble Hygiene and Health Care Ltd. (PGHHCL) is one of India’s fastest growing FMCG companies that has in its portfolio Whisper– India’s leading Feminine Hygiene brand, and Vicks – India’s No. 1 Health Care brand and Old Spice. The company has carved a reputation for delivering superior products to meet the needs of consumers. PGHHCL is committed to making every day in the lives of Indian consumers better through the quality of its products and the sincerity of its service. Please visit [in.pg.com](http://in.pg.com) for the latest news.

**For details contact: Madison Public Relations: Malika Bhavnani +91 9820496099; [malika.bhavnani@madisonpr.in](mailto:malika.bhavnani@madisonpr.in)**

# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

**REVIEW REPORT TO  
THE BOARD OF DIRECTORS  
PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED** ("the Company") for the quarter and nine months ended March 31, 2022, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, (initialled by us for identification). This Statement, which is the responsibility of the Company's Management, has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on April 28, 2022, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For KALYANIWALLA & MISTRY LLP  
CHARTERED ACCOUNTANTS**

Firm Reg. No.: 104607W / W100166



**Roshni R. Marfatia  
PARTNER**

M. No.: 106548

UDIN: **22106548AHYXTS5192**

Mumbai, April 28, 2022.

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001  
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275